We believe that transforming cancer care requires the development of integrated solutions that combine an ability to understand how cancers vary from patient to patient with novel therapeutics that address the underlying dynamics of tumor biology and anticipate the potential for resistance. Merrimack currently has six oncology therapeutics in clinical development, multiple product candidates in preclinical development and an active Systems Biology-driven discovery effort.
Merrimack believes that improving cancer care requires a systems-based understanding of the dynamic interactions within a cancer cell and its environment. Click below to learn more about our systems approach and how we’re applying it to improve the treatment of cancer.
Browse our library to explore published research papers, clincal data, conference presentations and featured scientific news and events related to Merrimack.
MM-111 is a first-in-class bispecific antibody that has been shown in preclinical studies to bind with both specificity and avidity to HER2 and HER3 expressing tumor cells. The HER2 arm is responsible for initial tumor cell targeting and docking, while the therapeutic HER3 arm is designed to block heregulin-induced cell signaling.
MM-151 is an oligoclonal therapeutic consisting of a mixture of three fully human monocolonal antibodies designed to bind and inhibit signaling of the Epidermal Growth Factor Receptor (EGFR).
MM-141 is a monoclonal antibody that acts as a tetravalent inhibitor of PI3K/AKT/mTOR, which is a major pro-survival pathway tumor cells use as a resistance mechanism to anti-cancer therapies.
MM-131 is currently in preclinical development.
MM-302 is a HER2-targeted nanotherapeutic consisting of the chemotherapeutic doxorubicin, encapsulated in a liposomal sphere. Doxorubicin has been a standard therapy for the treatment of breast cancer for more than 30 years.
MM-310 is currently in preclinical development.